PROC (Procaps Group) Interest Coverage : 1.21 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Procaps Group's Operating Income for the three months ended in Sep. 2023 was $13.0 Mil. Procaps Group's Interest Expense for the three months ended in Sep. 2023 was $-10.8 Mil. Procaps Group's interest coverage for the quarter that ended in Sep. 2023 was 1.21. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Procaps Group's Interest Coverage or its related term are showing as below:

PROC' s Interest Coverage Range Over the Past 10 Years
Min: 0.82 Med: 1.02 Max: 1.51
Current: 0.85

PROC's Interest Coverage is ranked worse than
93.52% of 664 companies
in the Drug Manufacturers industry
Industry Median: 12.275 vs PROC: 0.85

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Procaps Group Interest Coverage Historical Data

The historical data trend for Procaps Group's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Procaps Group Interest Coverage Chart

Procaps Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Interest Coverage

0.87

1.17

0.82

1.51

Procaps Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Coverage	Get a 7-Day Free Trial											2.74	0.16	0.36	1.42	1.21

Competitive Comparison of Procaps Group's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procaps Group's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Procaps Group's Interest Coverage falls into.

Procaps Group Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Procaps Group's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Procaps Group's Interest Expense was $-25.8 Mil. Its Operating Income was $39.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $28.4 Mil.

Interest Coverage	=	-1	*	Operating Income (A: Dec. 2022 )	/	Interest Expense (A: Dec. 2022 )
	=	-1	*	38.973	/	-25.762
	=	1.51

Procaps Group's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, Procaps Group's Interest Expense was $-10.8 Mil. Its Operating Income was $13.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $220.7 Mil.

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2023 )	/	Interest Expense (Q: Sep. 2023 )
	=	-1	*	13.049	/	-10.769
	=	1.21

The higher the ratio, the stronger the company's Financial Strength is.

Procaps Group (NAS:PROC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Procaps Group Interest Coverage Related Terms

Thank you for viewing the detailed overview of Procaps Group's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Procaps Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

9X1:Germany

Address

9 Rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.procapsgroup.com

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Executives

Alexandre Weinstein Manieu	director, 10 percent owner	CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski	director, 10 percent owner, officer: Chief Executive Officer	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski	director, 10 percent owner	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust	10 percent owner	OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a.	10 percent owner	3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371